(Note: Super Plus Acquisition Corp. withdrew its plans for its SPAC IPO in an SEC filing dated July 24, 2023. The S-1 was filed on Sept. 10, 2021.) We primarily intend to focus on acquiring a growth-oriented business with an enterprise value between $100 million and $300 million. Although there is no restriction or limitation on what industry […]

Ultimax Digital aims to combine the element of a video game studio and publisher, known as the Ultimax Game Studio,  with a marketplace for Non-Fungible Tokens (NFTs), known as the Ultimax NFT Marketplace, along with an NFT creation middleware developer, known as the Ultimax NFT Toolkit, and an NFT studio that produces NFTs to sell […]

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. If nuclease gene editing approaches are “scissors” for the genome, and […]

(Note: ScoutCam Inc., an Israeli micro medical imaging company, withdrew its plans for a NASDAQ uplisting from the OTC Market in an SEC filing dated Sept. 23, 2022.) We are engaged in the development, production and marketing of innovative miniaturized imaging equipment known as our micro ScoutCam™ portfolio for use in medical procedures as well […]

(Note: This is NOT an IPO. This is an NYSE-American uplisting from the OTC Pink Marketplace. In an S-1/A filing dated Oct. 11, 2022, Castellum, Inc. cut the size of its public offering (in connection with the NYSE-American uplisting) to 1.5 million shares at a price range of $2.00 to $3.00 each – down from […]

Asset Entities is a technology company providing social media marketing and content delivery services across Discord, TikTok and other social media platforms. (Incorporated in Nevada) We also design, develop and manage servers for communities on Discord. Based on the rapid growth of our Discord servers and social media following, we have developed three categories of […]

(Note: Cadrenal Therapeutics Inc. priced its IPO on Jan. 19, 2023, in sync with the terms in its prospectus: 1.4 million shares at $5.00 to raise $7.0 million. Cadrenal Therapeutics, Inc. added Sutter Securities as a joint book-runner with Boustead Securities (previously sole book-runner) in an S-1/A filing dated Dec. 8, 2022. Previously: Cadrenal Therapeutics […]

(Note: DMB Acquisition Corp. withdrew its SPAC IPO in an SEC filing dated Sept. 22, 2022. This blank check company’s IPO had been in the works since July 2021. Unlike most SPAC IPOs, this deal was planned as a stock-only offering – no warrants.) We intend to focus on businesses that have their primary operations located […]

(Note: Melt Pharmaceuticals, Inc. withdrew its IPO plans in an SEC filing dated Jan. 4, 2023.) Melt is a clinical stage pharmaceutical company focused on the development and commercialization of proprietary non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient and in-office settings. We intend to seek regulatory approval through the […]

(Eleison Pharmaceuticals Inc. withdrew its IPO plans in an SEC letter dated June 28, 2023. The cancer biotech filed its S-1  in Jan. 24, 2022. It never filed terms.)  We are a clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare life-threatening […]